Effect of Continuous Glucose Monitoring on Hypoglycemia in Adults With Pancreatogenic Diabetes
Key facts
- Who runs it
- Aalborg University Hospital
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 30 people enrolled
- Started
- 8 Sept 2022
- Ended
- 5 Jun 2024
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Continuous glucose monitoring
- Record updated
- 4 October 2024
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Signed informed consent before any study specific procedures
- Able to read and understand Danish
- Male or female age ≥ 18 ≤ 85 years
- A definitive diagnosis of chronic pancreatitis based on the M-ANNHEIM criteria
- A diagnosis of insulin treated pancreatogenic diabetes based on the World Health Organization criteria for diabetes (HbA1c ≥6.5 % (48 mmol/mol) and/or fasting plasma glucose ≥126 mg/dl (7.0 mmol/l)) >3 months after diagnosis of pancreatitis
Who cannot take part
- Attack of acute on chronic pancreatitis requiring admission within four weeks prior to inclusion
- Use of glucocorticoid medications within four weeks prior to inclusion, with the exception of inhaled glucocorticoids in the treatment of chronic pulmonary diseases
- Prior pancreatic surgery (including total pancreatectomy, pancreaticoduodenectomy, distal pancreatectomy, pancreaticojejunostomy, enucleation, or Frey procedure)
- Prior gastric surgery or vagotomy
- Known or suspected abdominal cancer (incl. intestine, pancreas, and the hepato-biliary system)
- Presence of autoimmune antibodies suggestive of type 1 diabetes
- Autoimmune pancreatitis
- Severe pre-existing comorbidities (assessed by investigator upon inclusion)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will investigate the effect of continuous glucose monitoring (CGM) (compared to self-monitoring) on hypoglycemia and glycemic control in patients with insulin-treated pancreatogenic diabetes.
The 2 groups in the trial
- Continuous glucose monitoringTreatment being tested
Participants will monitor their glucose levels using CGM with access to interstitial glucose levels continuously throughout the day. Each study period is preceded by 20 days of masked CGM assessment.
- Self-monitoring of blood glucoseNo study treatment, for comparison
Participants will monitor their blood glucose levels using a glucometer and a capillary blood sample from finger-pricking. Participants will in addition use masked CGM for the last 20 days of the study period to monitor glucose levels for comparison. Each study period is preceded by 20 days of masked CGM assessment.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 4 October 2024